Oral DS107G in Moderate to Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study will compare the safety and efficacy of DS107G (2 g) to placebo in patients with
moderate to severe atopic dermatitis.
DS107G capsules (2 g) will be orally administered for 8 weeks, and will be compared against
placebo.
This study will enroll approximately 100 adult patients.